Scholar Rock Resubmits Apitegromab BLA, Expands Manufacturing Plans

The latest announcement is out from Scholar Rock Holding ( (SRRK) ).

On March 31, 2026, Scholar Rock announced it had resubmitted its biologics license application to the U.S. Food and Drug Administration for apitegromab, a first-in-class muscle-targeted therapy that has shown statistically significant and clinically meaningful motor function gains in a pivotal Phase 3 trial in spinal muscular atrophy patients on SMN-targeted treatments. The resubmission, made in alignment with the FDA after addressing issues tied to a prior complete response letter related to Catalent Indiana’s facility, now includes both the Novo Nordisk-owned site and a second U.S.-based fill-finish plant to bolster supply, with the company expecting BLA acceptance within 30 days, a review of up to six months, a potential PDUFA decision in late September 2026, and an EMA ruling on its European application around mid-2026, developments that could materially advance its path toward global commercial launches.

Scholar Rock’s decision to proceed with the BLA resubmission before a formal reinspection of Catalent Indiana follows a series of Type A and Type C meetings and site interactions in late 2025 and early 2026, during which regulators did not request further corrective actions and agreed to the inclusion of the second facility based on accelerated qualification timelines. The limited-scope resubmission, primarily adding a standard safety update and expanded manufacturing capacity, signals increasing regulatory alignment and supply-chain readiness for apitegromab, potentially strengthening Scholar Rock’s competitive position in SMA and supporting anticipated demand if U.S. and European approvals are ultimately granted.

The most recent analyst rating on (SRRK) stock is a Hold with a $41.00 price target. To see the full list of analyst forecasts on Scholar Rock Holding stock, see the SRRK Stock Forecast page.

Spark’s Take on SRRK Stock

According to Spark, TipRanks’ AI Analyst, SRRK is a Neutral.

The score is held back primarily by weak financial performance (zero revenue, expanding losses, and substantial cash burn), which increases financing risk. Offsetting this, the latest earnings call highlighted meaningful regulatory and commercial progress toward a 2026 launch and improved funding flexibility, while technicals are constructive with the stock trading above major moving averages. Valuation remains challenging given negative earnings.

To see Spark’s full report on SRRK stock, click here.

More about Scholar Rock Holding

Scholar Rock Holding Corporation is a late-stage biopharmaceutical company focused on developing and commercializing apitegromab for children and adults with spinal muscular atrophy and other rare, severe neuromuscular diseases. Leveraging a proprietary platform in myostatin biology to advance muscle-targeted monoclonal antibodies, the Cambridge, Mass.-based company aims to improve musculoskeletal health across a global commercial footprint.

Average Trading Volume: 1,227,313

Technical Sentiment Signal: Buy

Current Market Cap: $4.95B

Find detailed analytics on SRRK stock on TipRanks’ Stock Analysis page.